271 related articles for article (PubMed ID: 28686074)
1. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
[TBL] [Abstract][Full Text] [Related]
3. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
[TBL] [Abstract][Full Text] [Related]
4. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.
Zhang F; Duan S; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Sci; 2016 Jun; 107(6):746-54. PubMed ID: 27009878
[TBL] [Abstract][Full Text] [Related]
6. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
Circu M; Cardelli J; Barr MP; O'Byrne K; Mills G; El-Osta H
PLoS One; 2017; 12(9):e0184922. PubMed ID: 28945807
[TBL] [Abstract][Full Text] [Related]
7. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
8. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
9. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
10. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
11. NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer.
Zhu R; Xue X; Shen M; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Exp Cell Res; 2019 Jan; 374(1):181-188. PubMed ID: 30508513
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
Lu T; Lu W; Jia C; Lou S; Zhang Y
Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
15. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
[TBL] [Abstract][Full Text] [Related]
16. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
18. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
19. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
